发明授权
US08889701B1 Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
有权
取代的(S) - (2R,3R,5R)-3-羟基 - (5-嘧啶-1-基)四氢呋喃-2-基甲基芳基氨基磷酸酯
- 专利标题: Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
- 专利标题(中): 取代的(S) - (2R,3R,5R)-3-羟基 - (5-嘧啶-1-基)四氢呋喃-2-基甲基芳基氨基磷酸酯
-
申请号: US14051464申请日: 2013-10-11
-
公开(公告)号: US08889701B1公开(公告)日: 2014-11-18
- 发明人: Alexandre Vasilievich Ivachtchenko , Andrey Alexandrovich Ivashchenko , Oleg Dmitrievich Mitkin
- 申请人: Alla Chem, LLC
- 主分类号: A01N43/54
- IPC分类号: A01N43/54 ; A61K31/505 ; A61K45/06 ; C07F9/6558 ; A61K31/695 ; A61K31/675
摘要:
The instant invention relates to a novel compound representing a substituted phosphoramidic acid—a (2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-yl)methyl aryl phosphoramidate of formula 1 or a (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-yl)methyl aryl phosphoramidate of formula 2, or a pharmaceutically acceptable salt, a hydrate, a crystalline form or a stereoisomer thereof, as defined in the specification.The novel compound is used for a pharmaceutical composition with at least one pharmaceutically acceptable excipient as well as with an inosine 5 monophosphate dehydrogenase inhibitor, HCV protease NS3 inhibitor, HCV protease NS3/4A inhibitor, and RNA polymerase NS5A inhibitor. The novel compound is useful as a viral polymerase HCV NS5B inhibitor and can be used for treating a disease caused by hepatitis C virus (HCV).
信息查询
IPC分类: